Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7132416 | ALBIREO | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep, 2022
(1 year, 23 days ago) | |
US10975046 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10093697 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
US10981952 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
US9694018 | ALBIREO | IBAT inhibitors for the treatment of liver disease |
Nov, 2031
(8 years from now) | |
US10011633 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
US10487111 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
US11365182 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
US11583539 | ALBIREO | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
Nov, 2041
(18 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 20, 2026 |
Orphan Drug Exclusivity (ODE) | Jul 20, 2028 |
New Indication (I) | Jun 13, 2026 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 2025-07-20
Market Authorisation Date: 20 July, 2021
Treatment: Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of reducing serum bile acids in patients 3 months or older sufferi...
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic